VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZNTL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZNTLZentalis Pharmaceuticals, Inc.
$1.49$106M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksZNTLFinancials

Zentalis Pharmaceuticals, Inc. (ZNTL) Income Statement

8Y historyFree accessUpdated daily

Revenue has been effectively absent in most recent quarters while operating margin deteriorated to -185.6% in 2024Q4 and R&D intensity dominated a cost base reaching $63.9M per quarter, suggesting expense growth is not being offset by any top-line contribution.

Income StatementBalance SheetCash FlowRatios

ZNTL Income Statement

Annual statement

ZNTL Income Statement

Zentalis Pharmaceuticals, Inc. (ZNTL) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Sales/Revenue0067.42M0000014K
Revenue Growth %-100%-100%------100%-
Cost of Goods Sold151K00000000
COGS % of Revenue---------
Gross Profit-151K067.42M0000014K
Gross Margin %--100%-----100%
Gross Profit Growth %--100%------100%-
Operating Expenses150.64M152.81M258.62M299.51M227.29M216.54M118.79M46.84M23.8M
OpEx % of Revenue--383.57%-----169978.57%
Selling, General & Admin34.94M37.72M87.11M59.4M54.55M40.94M33.89M8.46M4.88M
SG&A % of Revenue--129.2%-----34828.57%
Research & Development115.7M107.3M167.77M235.16M172.73M175.6M84.9M38.39M18.92M
R&D % of Revenue--248.82%-----135150%
Other Operating Expenses07.8M3.74M4.95M00000
Operating Income-150.79M-152.81M-191.19M-299.51M-227.29M-216.54M-118.79M-46.84M-23.78M
Operating Margin %---283.57%------169878.57%
Operating Income Growth %-20.08%36.16%-31.78%-4.96%-82.29%-153.57%-96.97%-
EBITDA-150.18M-152.07M-189.91M-298.12M-225.86M-216M-118.63M-46.73M-23.73M
EBITDA Margin %---281.65%------169514.29%
EBITDA Growth %8.63%19.92%36.3%-31.99%-4.57%-82.08%-153.83%-96.92%-
D&A (Non-Cash Add-back)613K739K1.29M1.39M1.43M544K160K111K51K
EBIT-140.85M-145.01M-187.46M-248.99M-235.01M-207.74M-118.79M-46.84M-23.78M
Net Interest Income0000-2.57M00498K355K
Interest Income00002.26K00498K355K
Interest Expense00002.58M0000
Other Income/Expense9.94M16.19M25.5M6.6M-10.29M50.15M683K482K355K
Pretax Income-140.85M-136.62M-165.69M-292.91M-237.58M-166.39M-118.1M-46.36M-23.43M
Pretax Margin %---245.74%------167342.86%
Income Tax818K442K177K-601K-469K-297K444K15K4K
Effective Tax Rate %-0.58%-0.32%-0.11%0.21%0.2%0.18%-0.38%-0.03%-0.02%
Net Income-141.67M-137.06M-165.84M-292.19M-236.81M-158.72M-117.84M-45.66M-21.07M
Net Margin %---245.96%------150478.57%
Net Income Growth %5.12%17.35%43.24%-23.39%-49.19%-34.69%-158.07%-116.75%-
Net Income (Continuing)-141.67M-137.06M-165.87M-292.31M-237.11M-166.09M-118.55M-46.38M-23.43M
Discontinued Operations000000000
Minority Interest000107K221K528K24.8M6.82M7.54M
EPS (Diluted)-1.67-1.91-2.33-4.47-4.48-3.72-2.87-1.29-1.17
EPS Growth %7.69%18.03%47.87%0.22%-20.43%-29.62%-122.48%-10.26%-
EPS (Basic)--1.91-2.33-4.47-4.48-3.72-2.87-1.29-1.17
Diluted Shares Outstanding84.61M71.87M71.08M65.41M52.86M42.69M41.04M35.88M18.06M
Basic Shares Outstanding84.61M71.87M71.08M65.41M52.86M42.69M41.04M35.88M18.06M
Dividend Payout Ratio---------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Sustained operating losses with no revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Stream Essentially Absent Recently

Based on the supplied quarterly income statement data, ZNTL reported revenue of $40.6M in 2024Q1 and $26.9M in 2024Q4, with no reported revenue in the intervening and subsequent quarters, making top-line trajectory difficult to assess.

The revenue line is sporadic and lumpy rather than recurring, which suggests reliance on collaboration, licensing, or milestone receipts rather than a commercial product base. Given that most quarters show zero revenue, growth-rate metrics are not meaningful, and investors should monitor whether any future revenue is recurring or one-time in nature. The absence of a stable revenue base warrants further investigation into the timing and durability of any future receipts.

Operating Losses Persist Despite Cost Controls

As reported in the quarterly figures, ZNTL's operating loss widened to -$82.2M in 2026Q2 from -$37.9M in 2026Q1, with R&D rising to $63.9M, indicating expense growth outpacing any revenue offset.

Operating income has remained negative across all ten reported quarters, meaning there is no evident operating leverage to date since there is little gross profit to scale against. The R&D line is the dominant cost driver, and its sharp increase in the most recent quarter suggests a deliberate step-up in clinical spending that may indicate pipeline advancement but also raises the cash consumption burden. SG&A has fluctuated materially, which may reflect timing effects rather than structural efficiency gains.

Net Losses Dominated by Operating Expense

Based on reported figures, ZNTL's EPS swung from a positive $0.14 in 2024Q1 to a loss of -$1.10 in 2026Q2, while stock-based compensation reached $31.4M in 2024Q4, a significant non-cash component.

The positive 2024Q1 net income appears to reflect a one-off revenue recognition rather than sustainable profitability, as subsequent quarters returned to losses. Stock-based compensation is a material non-cash charge that inflates the apparent operating burden relative to cash spending, though the R&D and SG&A lines still represent real economic costs. The large EPS volatility suggests net results are heavily influenced by lumpy revenue and non-operating timing rather than an underlying earnings trend.

R&D Intensity Defines the Cost Structure

Per the supplied income statement, R&D expense ranged from $22.9M to $63.9M per quarter across the period, representing the predominant operating cost and effectively all of the company's cost base in most periods.

The cost structure is clearly weighted toward research and development, which is typical of clinical-stage biotechnology but means expense discipline is best judged through R&D trajectory relative to clinical milestones. SG&A has been comparatively modest but volatile, moving between roughly $7M and $40M per quarter. Investors should monitor whether R&D spending translates into pipeline progress that justifies the continued burn rate.

Burn Rate and Dilution Risk Loom

Based on the reported quarterly losses, ZNTL's most recent net loss of -$77.6M against a backdrop of no reported revenue suggests the company may depend on external capital, which could pressure per-share economics through dilution.

The bear case centers on the persistence of losses and the lack of a visible revenue base, which could leave the company reliant on equity or debt financing if it cannot fund operations internally. The sharp acceleration in quarterly net loss from prior periods warrants scrutiny of cash runway, though the supplied income statement alone does not establish financing access or liquidity position. Investors should treat the absence of profitability as a material analytical concern until revenue becomes recurring.

ZNTL — Frequently Asked Questions

Quick answers to the most common questions about buying ZNTL stock.

What was Zentalis Pharmaceuticals, Inc.'s (ZNTL) revenue in 2025?

For fiscal year 2025, Zentalis Pharmaceuticals, Inc. (ZNTL) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.0M in 2018.

Is Zentalis Pharmaceuticals, Inc. (ZNTL) profitable?

Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $137.1M for the fiscal year ending 2025.